Somatic Cell Reprogramming via Epigenetic Modifiers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for cell reprogramming fail to produce stable, non-cancerous, and functional neural stem cells and progenitor cells, often resulting in transient phenotypical changes or cancerous cells, and rely on embryonic or fetal tissues that pose ethical and practical challenges.
Innovation Solution
A method involving transient increase of reprogramming agents like Msi1 and Ngn2 polypeptides, along with histone acetylation and DNA demethylation inhibitors, to induce stable expression of neural stem cell markers and genes, allowing the transformation of somatic cells into Neural Stem-Like Cells (NSLCs) capable of differentiating into neuronal and glial lineages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If forced gene expression is used to change cell phenotype, then cell type transformation is achieved, but the cells slowly revert back to original state and require constant artificial maintenance
Solution Approach 1:
The patent uses preliminary action by first transiently increasing reprogramming agents (Msi1, Ngn2, MBD2) to induce chromatin remodeling and DNA demethylation, which prepares the cell for stable phenotype change. This preliminary chromatin modification enables subsequent stable expression of neural stem cell markers without requiring continuous forced gene expression.
Solution Approach 2:
The patent applies parameter changes by modifying epigenetic parameters (histone acetylation levels, DNA methylation status) rather than relying solely on continuous forced gene expression. By changing these biochemical parameters through transient treatment with reprogramming agents and epigenetic modifiers, the cell achieves stable phenotype transformation that maintains itself without constant artificial intervention.
2Reliability
If embryonic or fetal tissues are used as cell sources, then stable stem cells are obtained, but ethical concerns and practical challenges arise
Solution Approach 1:
The patent applies copying by creating induced Neural Stem-Like Cells (iNSLCs) that replicate the functional properties of embryonic/fetal neural stem cells without using actual embryonic or fetal tissue. Through forced expression of Msi1, Ngn2, and MBD2 in somatic cells, the patent generates a copy of neural stem cell characteristics that can be used therapeutically without ethical concerns related to embryo destruction or fetal tissue procurement.
Solution Approach 2:
The patent uses somatic cells as an intermediary substrate to achieve the desired neural stem cell phenotype. Instead of directly using embryonic or fetal tissues, the patent transforms readily available somatic cells into neural stem-like cells through epigenetic reprogramming, thereby avoiding the harmful factors associated with embryonic/fetal tissue use while maintaining therapeutic utility.
3Ease of operation
If transient phenotypical changes are induced in somatic cells, then cell markers change, but the changes are not stable and revert when original conditions are restored
Solution Approach 1:
The patent applies preliminary action by first transiently increasing reprogramming agents (Msi1, Ngn2, MBD2) to induce chromatin remodeling and DNA demethylation, which prepares the cell for stable phenotype change. This preliminary chromatin modification enables subsequent stable expression of neural stem cell markers without requiring continuous forced gene expression.
Solution Approach 2:
The patent applies parameter changes by modifying epigenetic parameters (histone acetylation levels, DNA methylation status) rather than relying solely on continuous forced gene expression. By changing these biochemical parameters through transient treatment with reprogramming agents and epigenetic modifiers, the cell achieves stable phenotype transformation that maintains itself without constant artificial intervention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach generates stable, potent NSLCs that can be used for therapeutic applications without immunological rejection or ethical concerns, offering a more potent and cost-effective alternative to traditional cell sources.
Implementation Method 1
histone acetylation and DNA demethylation inhibitors, to induce stable expression of neural stem cell markers and genes
Implementation Method 2
histone acetylation and DNA demethylation inhibitors, to induce stable expression of neural stem cell markers and genes
Data Source
AI summary
A method of obtaining a pancreatic multipotent or unipotent cell including providing a cell of a first type which is not a pancreatic multipotent or unipotent cell; contacting the cell of a first type with an agent capable of remodeling the chromatin and/or DNA of the cell; transiently increasing expression of at least one pancreatic multipotent or unipotent gene regulator in the cell of a first type, to a level at which the at least one pancreatic multipotent or unipotent gene regulator is capable of driving transformation of the cell of a first type into the pancreatic multipotent or unipotent cell; and placing or maintaining the cell in a pancreatic cell culture medium and maintaining intracellular levels of the at least one pancreatic multipotent or unipotent gene regulator for a sufficient period of time to allow a pancreatic multipotent or unipotent cell to be obtained.